sRNAlytics

sRNAlytics is a biotechnology company focused on pioneering precision therapeutics that utilize small RNA molecules to address critical health issues. Their innovative approach leverages advanced technologies to enhance drug discovery and development. sRNAlytics specializes in the development of therapeutics centered around small RNA technologies. The company was co-founded by David Salzman and Neal Foster.

Based in San Francisco, US, sRNAlytics engaged in a DEAL in November 2017 when it raised an undisclosed amount of SEED funding from IndieBio and SOSV, marking its strategic entry into the biotech space led by CEO David Salzman. sRNAlytics develops precision therapeutics through its proprietary Code-Breaker™ platform, which utilizes artificial intelligence to dissect the intricate landscape of small RNAs (sRNAs). The company's primary focus is on creating biomarker-guided oligonucleotide therapeutics that target pulmonary, cardiac, neurological, and autoimmune diseases. By facilitating the discovery of novel drug targets and enhancing the understanding of disease mechanisms, sRNAlytics serves a diverse clientele that includes researchers, pharmaceutical firms, and healthcare providers across North America, Europe, and Asia.

sRNAlytics operates a revenue model based on partnerships and collaborations with biotech companies and research institutions. These partnerships typically involve co-development agreements where resources and expertise are shared to advance specific therapeutic targets. The company may also benefit from milestone-based payments that are contingent on the progression of clinical trials or regulatory approvals related to products derived from their platform. Specific transaction details and pricing structures are customized for each partnership and are not publicly disclosed.

To support its growth, sRNAlytics plans to expand its product offerings and enter new markets. The company is actively designing new therapeutics aimed at enhancing its Code-Breaker™ platform capabilities. Additionally, sRNAlytics intends to increase its presence in the Asian market by the end of 2024. The recent SEED funding secured in November 2017 will be utilized to bolster research and development efforts, specifically focusing on the advancement of its therapeutic pipeline and market expansion initiatives.